Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients

Gynecologic Oncology

Volumn 88, Issue 3, 2003, Pages 369-378

  Konstantinidou, Anastasia E ^a   Korkolopoulou, Penelope ^a   Vassilopoulos, Ioannis ^a   Tsenga, Artemis ^a   Thymara, Irene ^a   Agapitos, Emmanuel ^a   Patsouris, Efstratios ^a   Davaris, Panagiotis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Immunohistochemistry; Ki 67; Ovarian cancer; p21Cip1; p27Kip1; p53; Retinoblastoma gene protein

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PLATINUM; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; AGGRESSIVENESS; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REDUCTION; RETINOBLASTOMA; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

EID: 0037342840     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(02)00092-6     Document Type: Article

References (43)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J Clin. 49:1999;8-41.
2. Kamb A. Cell cycle regulators and cancer. Trends Genet. 11:1995;136-140.
3. Granna X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:1995;211-219.
4. Chellapan S.P., Hiebert S., Mudryj M., Horowitz J.M., Nevin J.R. The E2F transcription factor is a cellular target for the RB protein. Cell. 65:1991;1053-1061.
5. Luo Y., Hurwitz J., Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21/Cip1. Nature. 375:1995;159-161.
6. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
7. Polyak K., Lee M., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., et al. Cloning of p27Kip1, a cyclin-dependent kianse inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66.
8. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
9. Osborne R.J., Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer. 69:1994;429-438.
10. Yang-Feng T.L., Han H., Chen K.C., Li S.B., Claus B.E., Carcangiu M.L., et al. Allelic loss in ovarian cancer. Int J Cancer. 54:1993;546-551.
11. Kim T.M., Benedict W.F., Xu H.-J., Hu S.X., Gosewehr J., Velicescu M., et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumour and is associated with normal retinoblastoma gene expression. Cancer Res. 54:1994;605-609.
12. Li S.B., Schwartz P.E., Lee W.H., Yang-Feng T.L. Allele loss at the retinoblastoma locus in human ovarian cancer. J Natl Cancer Inst. 83:1991;637-640.
13. Liu Y., Heyman M., Wang Y., Falkmer U., Hisng C., Szekely L., et al. Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells. Int J Cancer. 58:1994;663-667.
14. Milner B.J., Allan L.A., Eccles D.M., Kitchener H.C., Leonard R.C.F., Kelly K.F., et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 53:1993;2128-2132.
15. Wan M., Cofer K.F., Dubleau L. WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer. Br J Cancer. 73:1996;1398-1400.
16. Kip1 chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors . Cancer Res. 55:1995;1211-1214.
17. Xu H.J. Altered retinoblastoma (Rb) protein expression in human malignancies. Adv Anat Pathol. 2:1995;213-226.
18. Hashiguchi Y., Tsuda H., Yamamoto K., Inoue T., Ishiko O., Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol. 32:2001;988-996.
19. Dong Y., Walsch M.D., McGuckin M.A., Cummings M.C., Gabrielli B.G., Wright G.R., et al. Reduced expression of retinoblastoma gene product (pRb) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer. 74:1997;407-415.
20. Kusume T., Tsuda H., Kawabata M., Inoue T., Umesaki N., Suzuki T., et al. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res. 5:1999;4152-4157.
21. Gerdes J. An immunohistological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery. Int J Cancer. 35:1985;169-171.
22. Sengupta P.S., McGown A.T., Bajaj V., Blackhall F., Swindell R., Bromley M., et al. p53 and related proteins in epithelial ovarian cancer. Eur J Cancer. 36:2000;2317-2328.
23. Russel P. Surface epithelial-stromal tumors of the ovary. Kurman R.J. Blaustein's pathology of the female genital tract. 4th ed:1994;705-782 Springer-Verlag, New York.
24. Serov SF, Scully R, Sobin LH. Histological typing of ovarian tumors. International histological classification of tumors n:9, Geneva: WHO.
25. Staging announcement. Gynecol Oncol. 25:1989;383-385.
26. Schmider A., Gee C., Friedmann W., Lukas J.L., Press M.F., Lichtenegger W., et al. p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol. 77:2000;237-242.
27. Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol. 85:2002;405-414.
28. Hakes T.B. Prognostic factors in ovarian cancer. Markman M., Hoskins W.J. Cancer of the ovary. 1993;115-131 Raven Press, New York.
29. Sasano H., Comerford J., Silverberg S.G., Garrett C.T. An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer. 66:1990;2150-2154.
30. Fang X., Jin X., Xu H.J., Liu L., Peng H.Q., Hogg D., et al. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene. 16:1998;1-8.
31. Dodson M.K., Cliby W.A., Xu H.J., DeLacey K.A., Hu S.X., Keeney G.L., et al. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res. 54:1994;610-613.
32. Havrilesky L.J., Alvarez A.A., Whitaker R.S., Marks J.R., Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol Oncol. 83:2001;491-500.
33. Gras E., Pons C., Muchin P., Matias-Guiu X., Prat J. Loss of heterozygosity at the RB-1 locus and pRb immunostaining in epithelial ovarian tumors. A molecular, immunohistochemical and clinicopathologic study. Int J Gynecol Pathol. 20:2001;335-340.
34. Taylor R.R., Linnoila R.I., Geradts J., Tenericllo G., Nash J.D., Park R.C., et al. Abnormal expression of the retinoblastoma gene in ovarian neoplasms and correlation to p53 and K-ras mutations. Gynecol Oncol. 58:1995;307-311.
35. Geradts J., Kratzke R.A., Crush-Stanton S., Wen S.F., Lincoln C.E. Wild-type and mutant retinoblastoma protein in paraffin sections. Mod Pathol. 9:1996;339-347.
36. Niemann T.H., Trgovac T.L., McGaughy V.R., Lewandowski G.S., Copeland L.J. Retinoblastoma protein expression in ovarian epithelial neoplasms. Gynecol Oncol. 69:1998;214-219.
37. Masciullo V., Sgambato A., Pacilio C., Pucci B., Ferrandina G., Palazzo J. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 59:1999;3790-3794.
38. Sui L., Dong Y., Ohno M., Sugimoto K., Tai Y., Hando T., et al. Implication of malignancy and prognosis of p27 (Kip1), cyclin E and CdK2 expression in epithelial ovarian tumors. Gynecol Oncol. 83:2001;56-63.
39. Xu H.J., Hu S.X., Benedict W.F. Lack of nuclear RB protein staining in G0/middle G1 cells correlation to changes in total Rb protein level . Oncogene. 6:1991;1139-1144.
40. Mateo M.S., Sanchez-Beato M., Martinez J.C., Orfao A., Orradre J.L., Piris M.A. p53, Rb and bcl-2 expression during the cell cycle a study in phytohaemagglutinin stimulated-lymphocytes and microwave irradiated lymphoid tissue sections . J Clin Pathol. 48:1995;151-159.
41. Korkolopoulou P., Kouzelis K., Christodoulou P., Papanikolaou A., Thomas-Tsagli E. Expression of retinoblastoma gene product and p21 (WAF1/Cip1) protein in gliomas correlations with proliferation markers, p53 expression and survival . Acta Neuropathol. 95:1998;617-624.
42. Korkolopoulou P.A., Angelopoulou M.K., Kontopidou F.N., Patsouris E.S., Christodoulou P.N., Kittas C.N., et al. Retinoblastoma gene product and p21 (WAF1/Cip1) protein expression in non-Hodgkin's lymphomas. A multivariate survival analysis. Leuk Lymphoma. 40:2001;647-658.
43. Anttila M.A., Kosma V.-M., Hongxiu J., Puolakka J., Jukola M., Saarikoski S., et al. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer. 79:1999;1870-1880.